Literature DB >> 17704947

Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats.

Eleftherios Vairaktaris1, Lambros Goutzanis, Stavros Vassiliou, Sofia Spyridonidou, Emeka Nkenke, Georgios Papageorgiou, Pashalis Strantzias, Andreas Lazaris, Christos Yapijakis, Efstratios Patsouris.   

Abstract

PURPOSE: The expression of erbB2 and erbB3 receptors was investigated in an experimental model of chemically induced oral carcinogenesis in normal and diabetic (type I) Sprague-Dawley rats.
METHODS: Thirteen diabetic and twelve normal rats developed precancerous and cancerous lesions after 4-nitroquinoline-N-oxide treatment, while six diabetic and six normal animals were used as controls. Sections of biopsies from all animals were classified histologically in the following categories: normal mucosa, hyperplasia, dysplasia, early invasion, well- and moderately-differentiated squamous cell carcinoma. Each section was studied immunohistochemically using monoclonal antibodies against erbB2 and erbB3 proteins and six representative histological regions in each section were analysed.
RESULTS: The erbB2 was expressed at very low levels in normal rats, while in diabetic animals its expression was significantly increased during early invasion (P = 0.04). The erbB3 expression was significantly elevated in well-differentiated carcinoma in normal animals (P = 0.01), while in diabetic animals it was significantly increased during oral mucosal hyperplasia and dysplasia (P = 0.03 and 0.0007, respectively). The comparison of erbB2 expression between diabetic and normal rats revealed significant differences in all stages except for the tumor stage of moderately differentiated carcinoma (P = 0.01, 0.00001, 0.00001, 0.003, and 0.00001). In regard to erbB3 expression, significant differences between diabetic and normal rats existed only in normal, non-cancerous and precancerous stages (P = 0.007, 0.0001, 0.0003).
CONCLUSIONS: It seems that diabetes enhances the expression of both erbB2 and erbB3 in certain stages of oral oncogenesis possibly resulting in promotion of cell proliferation and inhibition of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17704947     DOI: 10.1007/s00432-007-0289-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  46 in total

1.  Hepatic expression of ErbB3 is repressed by insulin in a pathway sensitive to PI-3 kinase inhibitors.

Authors:  R S Carver; P M Mathew; W E Russell
Journal:  Endocrinology       Date:  1997-12       Impact factor: 4.736

2.  Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.

Authors:  L Goutzanis; E Vairaktaris; C Yapijakis; N Kavantzas; E Nkenke; S Derka; S Vassiliou; Y Acil; P Kessler; N Stavrianeas; D Perrea; I Donta; P Skandalakis; E Patsouris
Journal:  Oral Oncol       Date:  2006-07-24       Impact factor: 5.337

3.  Expression of ErbB-3 and ErbB-4 protooncogene proteins in oral squamous cell carcinoma: a pilot study.

Authors:  Juan Carlos de Vicente; Isabel Esteban; Patricia Germanà; Antonino Germanà; José Antonio Vega
Journal:  Med Oral       Date:  2003 Nov-Dec

4.  Clinical significance of serum and urinary c-erbB-2 levels in colorectal cancer.

Authors:  Christos Tsigris; Anastasios J Karayiannakis; Andrew Zbar; Konstantinos N Syrigos; Nicolaos Baibas; Theodoros Diamantis; Dimitrios Alexiou
Journal:  Cancer Lett       Date:  2002-10-28       Impact factor: 8.679

5.  Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer.

Authors:  Christos Tsigris; Anastasios J Karayiannakis; Konstantinos N Syrigos; Andrew Zbar; Theodoros Diamantis; Nikolaos Kalahanis; Dimitrios Alexiou
Journal:  Anticancer Res       Date:  2002 Sep-Oct       Impact factor: 2.480

6.  Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma.

Authors:  S Shintani; T Funayama; Y Yoshihama; R E Alcalde; T Matsumura
Journal:  Cancer Lett       Date:  1995-08-16       Impact factor: 8.679

7.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

Review 8.  Neu and its ligands: from an oncogene to neural factors.

Authors:  E Peles; Y Yarden
Journal:  Bioessays       Date:  1993-12       Impact factor: 4.345

9.  Diabetes and oral tumors in Hungary: epidemiological correlations.

Authors:  Márta Ujpál; Orsolya Matos; György Bíbok; Anikó Somogyi; György Szabó; Zsuzsanna Suba
Journal:  Diabetes Care       Date:  2004-03       Impact factor: 19.112

10.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  3 in total

Review 1.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

2.  Immunohistochemical Assessment of HER3 Expression in Odontogenic Cysts.

Authors:  Marieh Honarmand; Shirin Saravani; Nazanin Kamyab; Mehdi Jahantigh; Molouk Torabi Parizi
Journal:  Iran Red Crescent Med J       Date:  2015-11-06       Impact factor: 0.611

3.  Cutaneous clear cell/signet-ring cell squamous cell carcinoma arising in the right thigh of a patient with type 2 diabetes: combined morphologic, immunohistochemical, and etiologic analysis.

Authors:  Nong-Rong Wang; Meng-Meng Wang; Lv Zhou; Ze-Lin Liu; Nan-Ping Chen; Jin-Ping Hu; Yan-Juan Deng; Xiao-Qing Qi; Xiao-Feng Huang; Yue Su; Si-Yao Zhang; Fei Tong; Yu Zhang; Qi Lu; Zi-Yu Zhu; Huan Deng
Journal:  Diagn Pathol       Date:  2016-04-11       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.